- $68.66m
- $43.24m
- $0.41m
Brief: MediciNova Announces Initiation Of Phase 2 Trial of MN-001 (Tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
Brief: Medicinova Announces Extension Of Barda Contract To Develop MN-166 (Ibudilast) As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury
Brief: Medicinova Inc - Effective June 16, Douglas Paulin Resigned As CFO
U.S. STOCKS ON THE MOVE-Grab Holdings Ltd, HeartCore Enterprises Inc, Twitter Inc
U.S. STOCKS ON THE MOVE-Omniq Corp, LumiraDx Ltd, Caterpillar Inc
U.S. STOCKS ON THE MOVE-J.Jill Inc, Roku Inc, DocuSign Inc
Brief: MediciNova Announces Results From Phase 2 Trial Of Treatment For Hospitalized COVID-19 Patients At Risk For ARDS
MediciNova rises as drug shows promise in COVID trial
MediciNova Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Medicinova Says Secondary Analysis Of Phase 2 Trial Of Mn-166 Showed Mn-166 Reduces Rates Of Heavy Drinking And Measures Of Alcohol Craving
Brief: Medicinova Says Genzyme Filed First Amended Complaint, Which Included Claim For Infringement Of A U.S. Patent, In A Lawsuit Previously Filed Against Novartis
Brief: Medicinova Receives Notice Of Allowance For New Patent Covering MN-001, MN-002 For Treatment Of Advanced Nash In Korea
Brief: MediciNova Announces MN-166 Identified As Promising Pharmacotherapy For Alcohol Use Disorder
MediciNova Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Medicinova Receives New Patent Covering MN-001
Brief: Medicinova Receives Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For Hepatic Ballooning In Canada
Brief: Medicinova Receives A Notice Of Intention To Grant For A New Patent Covering Mn-166 (Ibudilast) For The Treatment Of Alcohol Use Disorder In Europe
Brief: Medicinova Receives A Notice Of Intention To Grant For A New Patent Covering Mn-001 And Mn-002 For Hepatic Ballooning In Europe
Brief: Medicinova Receives Notice Of Allowance For New Patent Covering Mn-166 (Ibudilast) For Treatment Of Als